Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity

Journal of Lipid Research

Volumn 52, Issue 4, 2011, Pages 646-656

  Lan, Hong ^a   Cheng, Cliff C ^a   Kowalski, Timothy J ^a   Pang, Ling ^a   Shan, Lixin ^a   Chuang, Cheng Chi ^a   Jackson, James ^a   Rojas Triana, Alberto ^a   Bober, Loretta ^a   Liu, Li ^a   Voigt, Johannes ^a   Orth, Peter ^a   Yang, Xianshu ^a   Shipps Jr , Gerald W ^a   Hedrick, Joseph A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fatty acid binding protein 4; Free fatty acid; Pharmacokinetics; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; BIOVITRUM 2A; BMS 309403; FATTY ACID; FATTY ACID BINDING PROTEIN 4 INHIBITOR; FATTY ACID BINDING PROTEIN 5 INHIBITOR; GLUCOSE; HTS 01037; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PYRROLE DERIVATIVE; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPOLYSIS; MACROPHAGE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; DIETARY FATS; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, NONESTERIFIED; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPOLYSIS; MACROPHAGES; MICE; NEOPLASM PROTEINS; OBESITY; TRIGLYCERIDES;

EID: 79953315358     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M012757     Document Type: Article

References (33)

1. Furuhashi, M., and G. S. Hotamisligil. 2008. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7: 489-503.
2. Hotamisligil, G. S., R. S. Johnson, R. J. Distel, R. Ellis, V. E. Papaioannou, and B. M. Spiegelman. 1996. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274: 1377-1379.
3. Makowski, L., J. B. Boord, K. Maeda, V. R. Babaev, K. T. Uysal, M. A. Morgan, R. A. Parker, J. Suttles, S. Fazio, G. S. Hotamisligil, et al. 2001. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7: 699-705.
4. Shaughnessy, S., E. R. Smith, S. Kodukula, J. Storch, and S. K. Fried. 2000. Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2 - /-) after short-term high-fat feeding: functional compensation by the keratinocyte [correction of keritinocyte] fatty acid binding protein. Diabetes. 49: 904-911.
5. Hertzel, A. V., L. A. Smith, A. H. Berg, G. W. Cline, G. I. Shulman, P. E. Scherer, and D. A. Bernlohr. 2006. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab. 290: E814-E823.
6. Maeda, K., K. T. Uysal, L. Makowski, C. Z. Gorgun, G. Atsumi, R. A. Parker, J. Bruning, A. V. Hertzel, D. A. Bernlohr, and G. S. Hotamisligil. 2003. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes. 52: 300-307.
7. Maeda, K., H. Cao, K. Kono, C. Z. Gorgun, M. Furuhashi, K. T. Uysal, Q. Cao, G. Atsumi, H. Malone, B. Krishnan, et al. 2005. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 1: 107-119. (Pubitemid 43960591)
8. Tuncman, G., E. Erbay, X. Hom, I. De Vivo, H. Campos, E. B. Rimm, and G. S. Hotamisligil. 2006. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. USA. 103: 6970-6975.
9. Sulsky, R., D. R. Magnin, Y. Huang, L. Simpkins, P. Taunk, M. Patel, Y. Zhu, T. R. Stouch, D. Bassolino-Klimas, R. Parker, et al. 2007. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg. Med. Chem. Lett. 17: 3511-3515.
10. Kurian, E., W. R. Kirk, and F. G. Prendergast. 1996. Affinity of fatty acid for (r)rat intestinal fatty acid binding protein:further examination. Biochemistry. 35: 3865-3874.
11. Furuhashi, M., G. Tuncman, C. Z. Gorgun, L. Makowski, G. Atsumi, E. Vaillancourt, K. Kono, V. R. Babaev, S. Fazio, M. F. Linton, et al. 2007. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid- binding protein aP2. Nature. 447: 959-965. (Pubitemid 46975747)
12. Barf, T., F. Lehmann, K. Hammer, S. Haile, E. Axen, C. Medina, J. Uppenberg, S. Svensson, L. Rondahl, and T. Lundback. 2009. N-benzyl-indolo carboxylic acids: design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. Bioorg. Med. Chem. Lett. 19: 1745-1748.
13. Ringom, R., E. Axen, J. Uppenberg, T. Lundback, L. Rondahl, and T. Barf. 2004. Substituted benzylamino-6-(trifluoromethyl)pyrimidin- 4(1H)-ones: a novel class of selective human A-FABP inhibitors. Bioorg. Med. Chem. Lett. 14: 4449-4452.
14. Lehmann, F., S. Haile, E. Axen, C. Medina, J. Uppenberg, S. Svensson, T. Lundback, L. Rondahl, and T. Barf. 2004. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg. Med. Chem. Lett. 14: 4445-4448.
15. van Dongen, M. J., J. Uppenberg, S. Svensson, T. Lundback, T. Akerud, M. Wikstrom, and J. Schultz. 2002. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. J. Am. Chem. Soc. 124: 11874-11880.
16. Veerkamp, J. H., R. A. Peeters, and R. G. Maatman. 1991. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim. Biophys. Acta. 1081: 1-24.
17. Hertzel, A. V., K. Hellberg, J. M. Reynolds, A. C. Kruse, B. E. Juhlmann, A. J. Smith, M. A. Sanders, D. H. Ohlendorf, J. Suttles, and D. A. Bernlohr. 2009. Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J. Med. Chem. 52: 6024-6031.
18. Cai, H., G. Yan, X. Zhang, O. Gorbenko, H. Wang, and W. Zhu. 2010. Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. Bioorg. Med. Chem. Lett. 20: 3675-3679.
19. Annis, D. A., E. Nickbarg, X. Yang, M. R. Ziebell, and C. E. Whitehurst. 2007. Affinity selection-mass spectrometry screening techniques for small molecule drug discovery. Curr. Opin. Chem. Biol. 11: 518-526.
20. Wunberg, T., M. Hendrix, A. Hillisch, M. Lobell, H. Meier, C. Schmeck, H. Wild, and B. Hinzen. 2006. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today. 11: 175-180.
21. Lo, M. C., A. Aulabaugh, G. Jin, R. Cowling, J. Bard, M. Malamas, and G. Ellestad. 2004. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332: 153-159.
22. Szebenyi, D. M., A. Arvai, S. Ealick, J. M. Laiuppa, and C. Nielsen. 1997. A system for integrated collection and analysis of crystallographic diffraction data. J. Synchrotron. Radiat. 4: 128-135.
23. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
24. Vagin, A., and A. Teplyakov. 2000. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56: 1622-1624.
25. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60: 2126-2132.
26. Roversi, P., E. Blanc, C. Vonrhein, G. Evans, and G. Bricogne. 2000. Modelling prior distributions of atoms for macromolecular refinement and completion. Acta Crystallogr. D Biol. Crystallogr. 56: 1316-1323.
27. Davies, J. Q., and S. Gordon. 2005. Isolation and culture of human macrophages. Methods Mol. Biol. 290: 105-116.
28. Coe, N. R., M. A. Simpson, and D. A. Bernlohr. 1999. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid Res. 40: 967-972.
29. Takashima, K., N. Matsunaga, M. Yoshimatsu, K. Hazeki, T. Kaisho, M. Uekata, O. Hazeki, S. Akira, Y. Iizawa, and M. Ii. 2009. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 157: 1250-1262.
30. Storch, J., and L. McDermott. 2009. Structural and functional analysis of fatty acid-binding proteins. J. Lipid Res. 50 ( Suppl. ): 126-131.
31. Yang, R., G. Castriota, Y. Chen, M. A. Cleary, K. Ellsworth, M. K. Shin, J. L. Tran, T. F. Vogt, M. Wu, S. Xu, et al. RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice. Int. J. Obes. (Lond.). Epub ahead of print. July 6, 2010; doi: 10.1038/ijo.2010.128.
32. Thompson, B. R., A. M. Mazurkiewicz-Munoz, J. Suttles, C. Carter-Su, and D. A. Bernlohr. 2009. Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling. J. Biol. Chem. 284: 13473-13480.
33. Smith, A. J., B. R. Thompson, M. A. Sanders, and D. A. Bernlohr. 2007. Interaction of the adipocyte fatty acid-binding protein with the hormone-sensitive lipase: regulation by fatty acids and phosphorylation. J. Biol. Chem. 282: 32424-32432.